TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: P-glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: P-Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with renal scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiac dysfunction prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADSI score of each Target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Global Constipation Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive value of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Pressure nasal injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of ascending single inhaled doses of GSK1995057
Endpoint domain: Adverse events/effects
Primary endpoint: Levels and specificity of anti-GSK1995057 binding antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma pharmacokinetics of ascending single inhaled doses of GSK1995057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response (undetectable serum HCV-RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endocrine remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VT/VF inducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychophysical data for taste solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in LDL-C Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in priapic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects with sustained undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Meconium concentration in amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Identification of occupational carcinogenic exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantification of Actinic Keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Achieving Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Abnormal Anal Cytology (ASC-US, ASC-H, LSIL, HSIL, Cancer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With High-grade Anal Dysplasia Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Length of the coronary segment evaluated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically assessed outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographically assessed outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood loss in the postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in EASI Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Elastance of Respiratory System, Lung and Chest Wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Ambulation Performance (FAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip, knee, and ankle fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip, knee, and ankle maximal volitional contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Bone Mineral Density (BMD) at the Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of pCLE diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with pain management application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diabetes distress Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease of inflammatory levels on blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resolution of Vaginal Bleeding and Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Survival at Day 30 Post Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Absence of ISHLT Primary Graft Dysfunction (PGD3) Grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in measurable lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of postoperative atelectasis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TD-9855 plasma exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients developing CDI during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Central blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of Renessans based triple therapy versus dual therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female pelvic floor questionnaires scoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of ventriculoperitoneal (VP) shunt infection
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Complete Wound Closure (Epithelialization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Urinary Peptide Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Motor skills performance parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 400m walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of effective gut cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Daily Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score Changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 8-year incidence of late AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of cannabis withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to local-regional recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Change in AOFAS Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients experiencing NCI grade 3 or 4 non-hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing treatment-related death
Endpoint domain: Mortality/survival
Primary endpoint: Recall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change from baseline in Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Level of HIV-1 RNA in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in FEV1 2 hours post inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Respiratory Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Distance Walked During 6 Minute Walk Time (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in EPIQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in OXFORD
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alteration in peripheral sensitisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knee Flexion Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-minute Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall SPADI Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of questions or concerns eliciting medical comments
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Effective corneal power calculation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-progression rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Glycine Increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily symptom score of allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily medication score of allergic rhinitis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measure of clonality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometriosis associated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow Mediated Dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival without pericardial effusion
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Fecal Immunochemical Test (FIT) Kit Return
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurophysiological measures - Active motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of pulmonary cathepsins, proteases inhibitors and GAGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post PE complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in muscle function testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relapse Free Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Change in prevalence of daily sunscreen use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Detrusor pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Menstrual Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotator cuff healing failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Combined rate of death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Positive predictive value of single nucleotide polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in absolute CD4 lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Engraftment and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events at Its Worst Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Events at Its Worst Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Exclusion of Abdominal Aortic Aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cerebrovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: need of intervention on renal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal function impairment (decrease in estimated GFR > 30% from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severe or very severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Study drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first hospital readmission or death
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Summed Pain Intensity Difference (SPID+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of volunteers with local and systemic reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut hormone secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Acute Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Substance P in the saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Velocity of MCA (VMCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: The diameter of the STA (superficial temporal artery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Headache
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FD of the pulmonary artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain intensity measured by 10cm VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serious and/or clinically significant infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of other serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Carotid Baroreflex Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Exercise Pressor Reflex Responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Recording Preferences to Restrict Provider Access to EHR Data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Providers' Opinion of Patients' Controlling EHR Access
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to decrease of tissue oxygenation index by 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent terminal half-life (t1/2?z)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Threshold Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of mesorectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall EEG interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adequate Clinical Response (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 Day Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of AT-101 in combination with rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: Disability of the Arm, Shoulder and Hand (DASH) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adrenal insufficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Subjects That Reach Pathological Downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum calcification propensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Serum Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in intracranial pressure (ICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in pain perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QTc Interval prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CDI Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Foot Function Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: walking distance in 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted hemoglobin increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment emergent antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cough-Specific Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Warwick-Edinburgh Mental Well Being Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PHQ9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression - Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in severity in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: using dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percent change in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success rate of chronic ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial implant micromotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With Poor Mental Health Quality of Life, MCS12≤ 40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life